Subventions financées

Brain disorders and disease represent an immense societal burden and the leading cost to the Canadian health care system.

Ependymal cells are a largely understudied barrier cell type in the brain that provide a wall between brain tissue and brain fluid (cerebral spinal fluid, CSF), playing an important role in regulating fluid balance.

In the past decade, rapid development of software has allowed detection of a wide variety of genetic risk factors in brain disorders.

Autism spectrum disorder (ASD) affects approximately 1 in 70 children and is associated to a considerable burden for affected individuals, their families, and health care at large.

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common and devastating neurological diseases, with over 750,000 AD patients and over 100,000 PD patients in Canada.

The MHCC, in collaboration with CSA Group (as the standards development organization), has championed the development of the CSA Z2003 Mental health and well-being for post-secondary students standard.

Parkinson’s Disease (PD) is a debilitating neurodegenerative disease for which there is no cure.

Optogenetics is a relatively new science subdomain that is revolutionizing brain research with great promises for therapeutics.